Lv1
32 积分 2024-05-19 加入
Comparison of Efficacy and Safety Profile of Allogeneic Versus Autologous CD19 Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies: A Systematic Review and Meta-Analysis
6天前
已完结
Comparison of Efficacy and Safety Profile of Allogeneic Versus Autologous CD19 Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies: A Systematic Review and Meta-Analysis
6天前
已关闭
New bispecific antibodies in diffuse large B-cell lymphoma
8天前
已完结
Efficacy and Safety of Dual-Targeting Chimeric Antigen Receptor-T Therapy for Relapsed or Refractory B Cel
14天前
已完结
Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1
17天前
已完结
Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1
17天前
已关闭
Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study
17天前
已完结
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
22天前
已完结
CD19 CAR-T treatment shows limited efficacy in r/r DLBCL with double expression and TP53 alterations
1个月前
已完结
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: Primary analysis of the ELM-1 study
1个月前
已完结
皖公网安备34019202002308
